Objective: To describe comorbidities and treatment charges in patients receiving initial anxiolytic therapy for anxiety disorders.
Design: Retrospective data analysis.
Patients: Six thousand six hundred forty-seven patients with anxiety disorders.
Measurements And Main Results: Analysis was conducted using medical and pharmacy data for patients in 26 United States health plans from the PharMetrics Integrated Outcomes database. Data were collected for 12 months before and after the first anxiolytic prescription date (index date) during the study period (January 1, 1998-December 31, 2000). The sample comprised patients with a diagnosis of anxiety disorder whose original anxiolytic prescription had been refilled within 120 days. International Classification of Diseases, 9th revision, Clinical Modification (ICD-9-CM) codes and medical and prescription data identified the existence of comorbidities, and medical and prescription charges. The most common diagnoses of anxiety disorder were anxiety not otherwise specified (67%), panic disorder (14%), and generalized anxiety disorder (13%). The most commonly prescribed anxiolytics were benzodiazepines, such as alprazolam (43%) and lorazepam (27%). Hypertension was the most common nonpsychiatric comorbidity (22%) and depression the most common psychiatric comorbidity (37%). Other comorbidities observed were lipid disorders (17%), chronic obstructive pulmonary disease (9%), and asthma (7%). Total treatment charges 12 months before and after initial anxiety diagnosis and anxiolytic prescription were dollar 6279 and dollar 9270, respectively (p < 0.0001).
Conclusion: Chronic conditions are commonly associated with anxiety disorders. Recognizing these psychiatric and nonpsychiatric comorbidities is important when treating patients with these disorders. Treatment charges are significantly higher when a patient is diagnosed with an anxiety disorder, highlighting the impact of anxiety on the total cost of treatment for these patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1592/phco.23.12.1251.32700 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Bioorthogonal reaction-mediated photosensitizer-peptide conjugate anchoring on cell membranes for enhanced photodynamic therapy.
Biomater Sci
January 2025
School of Engineering, Westlake University, Hangzhou, Zhejiang 310023, China.
Photodynamic therapy (PDT), utilizing a photosensitizer (PS) to induce tumor cell death, is an effective modality for cancer treatment. PS-peptide conjugates have recently demonstrated remarkable antitumor potential in preclinical trials. However, the limited cell membrane binding affinity and rapid systemic clearance have hindered their transition to clinical applications.
View Article and Find Full Text PDFThe prevalence and burden of musculoskeletal disorders amongst Indigenous people in Pimicikamak, northern Manitoba, Canada: A community health survey.
Prev Med Rep
January 2025
Faculty of Kinesiology and Recreation Management, University of Manitoba (Fort Garry campus), 420 University Crescent, Winnipeg, Manitoba R3T 2N2, Canada.
Objectives: To investigate the prevalence of spine symptoms and spine disability, self-care and care seeking behaviors in a random sample of Indigenous adults residing in Cross Lake, northern Manitoba, Canada.
Study Design And Setting: Orally administered survey in Cree or English to a representative sample of Pimicikamak citizens from the treaty ( = 150/1931 houses) and non-treaty ( = 20/92 houses) land, between May and July 2023. Questions ( = 154) were derived from the 2018 First Nations Regional Health Survey, 2020 Canadian Community Health Survey, and 2021 The Global Burden of Disease study, covering demographics, spine symptoms, chronic conditions, activity limitations, general health, self-care, medication, and satisfaction with care.
Optimized Rutin-incorporating PEGylated Nanoliposomes as a Model wit Remarkable Selectivity Against PANK1 and MCF7 Cell Lines.
Anticancer Agents Med Chem
January 2025
Cell Therapy Center, The University of Jordan, Amman, 11942, Jordan.
Background: This study aims to enhance the delivery of polyphenols using nanotechnology.
Objective: To develop and evaluate liposomal formulations for improved delivery and stability of polyphenols, specifically focusing on Rutin.
Methods: Liposomal formulations were meticulously prepared via the Thin-Film Hydration method.
Adhesive polyelectrolyte coating through UV-triggered polymerization on PLGA particles for enhanced drug delivery to inflammatory intestinal mucosa.
J Nanobiotechnology
January 2025
Department of Gastroenterology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, China.
Administering medication precisely to the inflamed intestinal sites to treat ulcerative colitis (UC), with minimized side effects, is of urgent need. In UC, the inflammation damaged mucosa contains a large number of amino groups which are positively charged, providing new opportunities for drug delivery system design. Here, we report an oral drug delivery system utilizing the tacrolimus-loaded poly (lactic-co-glycolic acid) (TAC/PLGA) particles with an adhesion coating by in situ UV-triggered polymerization of polyacrylic acid and N-hydroxysuccinimide (PAA-NHS).
View Article and Find Full Text PDFAssessing public support for air pollution mitigation and control policies: health, socioeconomic, and ideological predictors in an overburdened and vulnerable region of the U.S.
BMC Public Health
January 2025
Department of Public Health, University of California, Merced, 5200 N Lake Road, Merced, CA, 95343, USA.
Background: The San Joaquin Valley (SJV) in California is one of the most polluted regions in the U.S. This study examined favorability for air pollution mitigation policies, interventions, and identified predictors amongst region's residents.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!